Drug-Induced Liver Disease
|
0.400 |
GeneticVariation
|
phenotype |
BEFREE |
Genetic polymorphisms of CYP2E1 and GSTM1 loci and susceptibility to anti-tuberculosis drug-induced hepatotoxicity.
|
24903797 |
2014 |
Drug-Induced Liver Disease
|
0.400 |
GeneticVariation
|
phenotype |
BEFREE |
CYP2E1 RsaI/PstI polymorphism and risk of anti-tuberculosis drug-induced liver injury: a meta-analysis.
|
23131254 |
2012 |
Drug-Induced Liver Disease
|
0.400 |
GeneticVariation
|
phenotype |
BEFREE |
Update meta-analysis of the CYP2E1 RsaI/PstI and DraI polymorphisms and risk of antituberculosis drug-induced hepatotoxicity: evidence from 26 studies.
|
27062377 |
2016 |
Drug-Induced Liver Disease
|
0.400 |
GeneticVariation
|
phenotype |
BEFREE |
Among the patient-specific determinants of susceptibility to INH-associated DILI, the importance of HLA genetic variants has been increasingly recognized, whereas the role of polymorphisms of drug-metabolizing enzymes (NAT2 and CYP2E1) has become less important and remains controversial.
|
24783247 |
2014 |
Drug-Induced Liver Disease
|
0.400 |
GeneticVariation
|
phenotype |
BEFREE |
For the CYP2E1 gene, the RsaI polymorphism in the 5' untranslated region, and a polymorphic repetitive sequence at the CYP2E1 5'-flaking region were analyzed; there was no significant association between any CYP2E1 genotype and antituberculosis drug-induced hepatotoxicity.
|
17950035 |
2007 |
Drug-Induced Liver Disease
|
0.400 |
GeneticVariation
|
phenotype |
BEFREE |
The study suggests no association between the CYP2E1 genotyping with antituberculous drug-induced hepatotoxicity.
|
26997721 |
2017 |
Drug-Induced Liver Disease
|
0.400 |
GeneticVariation
|
phenotype |
BEFREE |
Relationship of anti-tuberculosis drug-induced liver injury and genetic polymorphisms in CYP2E1 and GST.
|
31697922 |
2020 |
Drug-Induced Liver Disease
|
0.400 |
GeneticVariation
|
phenotype |
BEFREE |
However, the combination of the CYP2E1 C1/C1 genotype with a slow acetylator NAT2 genotype increased the risk of anti-TB drug-induced hepatotoxicity (OR 5.33; P = 0.003) compared with the combination of a rapid acetylator NAT2 genotype with either a C1/C2 or C2/C2 genotype.5.
|
22506592 |
2012 |
Drug-Induced Liver Disease
|
0.400 |
GeneticVariation
|
phenotype |
BEFREE |
Conclusive evidence for association with DILI risk has been obtained for non-mutated CYP2E1, slow NAT2 and slow GSTM1 genotypes.
|
20214588 |
2009 |
Drug-Induced Liver Disease
|
0.400 |
GeneticVariation
|
phenotype |
BEFREE |
CYP2E1, GSTM1 and GSTT1 genetic polymorphisms and susceptibility to antituberculosis drug-induced hepatotoxicity: a nested case-control study.
|
22335459 |
2012 |
Drug-Induced Liver Disease
|
0.400 |
GeneticVariation
|
phenotype |
BEFREE |
Association of N-acetyltransferase 2 and cytochrome P450 2E1 gene polymorphisms with antituberculosis drug-induced hepatotoxicity in Western India.
|
23875638 |
2013 |
Drug-Induced Liver Disease
|
0.400 |
Biomarker
|
phenotype |
BEFREE |
To determine whether pharmacogenetic tests such as N-acetyltransferase 2 (NAT2) and cytochrome P450 2E1 (CYP2E1) genotyping are useful in identifying patients prone to antituberculosis drug-induced hepatotoxicity in a cosmopolite population.
|
16770646 |
2006 |
Drug-Induced Liver Disease
|
0.400 |
Biomarker
|
phenotype |
BEFREE |
Cytochrome P450 2E1 (CYP2E1) plays a vital role in drug-induced hepatotoxicity and cancers (e.g. lung and bladder cancer), since it is responsible for metabolizing a number of medications and environmental toxins to reactive intermediate metabolites.
|
31203697 |
2019 |
Drug-Induced Liver Disease
|
0.400 |
Biomarker
|
phenotype |
CTD_human |
Effects of CYP inhibitors on precocene I metabolism and toxicity in rat liver slices.
|
21741958 |
2011 |
Drug-Induced Liver Disease
|
0.400 |
Biomarker
|
phenotype |
CTD_human |
Cytochrome P450 2E1 genotype and the susceptibility to antituberculosis drug-induced hepatitis.
|
12668988 |
2003 |
Drug-Induced Liver Disease
|
0.400 |
Biomarker
|
phenotype |
BEFREE |
Volatile anaesthetics are known to cause drug-induced liver injury, a hepatotoxic reaction characterised by antibodies to trifluoroacetylated lipid and protein adducts and cytochrome p450 2E1.
|
30761577 |
2019 |
Drug-Induced Liver Disease
|
0.400 |
Biomarker
|
phenotype |
CTD_human |
Customised in vitro model to detect human metabolism-dependent idiosyncratic drug-induced liver injury.
|
28762043 |
2018 |
Drug-Induced Liver Disease
|
0.400 |
Biomarker
|
phenotype |
CTD_human |
To determine whether pharmacogenetic tests such as N-acetyltransferase 2 (NAT2) and cytochrome P450 2E1 (CYP2E1) genotyping are useful in identifying patients prone to antituberculosis drug-induced hepatotoxicity in a cosmopolite population.
|
16770646 |
2006 |
Drug-Induced Liver Disease
|
0.400 |
AlteredExpression
|
phenotype |
BEFREE |
Increased expression of CYP2E1 may represent the main factor contributing to oxidative stress-mediated liver damage in drug-induced liver injury (DILI).
|
31468699 |
2020 |